Cargando…

A Polypill for primary prevention of cardiovascular disease: A feasibility study of the World Health Organization

BACKGROUND: The feasibility of conducting a large-scale Polypill clinical trial in developing countries remains unclear. More information is needed regarding the efficacy in reducing the risk factors of cardiovascular disease (CVD), side effects, improvement in adherence and physician/patient "...

Descripción completa

Detalles Bibliográficos
Autores principales:	Soliman, Elsayed Z, Mendis, Shanthi, Dissanayake, Wasantha P, Somasundaram, Noel P, Gunaratne, Padma S, Jayasingne, I Kumudini, Furberg, Curt D
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3023675/ https://www.ncbi.nlm.nih.gov/pubmed/21205325 http://dx.doi.org/10.1186/1745-6215-12-3

Ejemplares similares

The feasibility of polypill for cardiovascular disease prevention in Asian Population
por: Sukonthasarn, Apichard, et al.
Publicado: (2020)

Strengths and Limitations of Using the Polypill in Cardiovascular Prevention
por: Roy, Ambuj, et al.
Publicado: (2017)

Medicinal herbs: Potential polypills in cardiovascular diseases
por: Noroozi, Samaneh, et al.
Publicado: (2021)

Multifactorial Prevention of Cardiovascular Disease in Patients with Hypertension: the Cardiovascular Polypill
por: Lafeber, M., et al.
Publicado: (2016)

Statins alone or polypill for primary prevention of cardiovascular diseases
por: Hasani-Ranjbar, Shirin, et al.
Publicado: (2016)

Could patents interfere with the development of a cardiovascular polypill?
por: Beall, Reed F., et al.
Publicado: (2016)

Redefining the polypill: pros and cons in cardiovascular precision medicine
por: Birla, Siddharth, et al.
Publicado: (2023)

Polypill—Friend or Foe?
por: Rishi, Rakesh Kumar
Publicado: (2011)

The polypill approach – An innovative strategy to improve cardiovascular health in Europe
por: Fuster, Valentín, et al.
Publicado: (2017)

The Polypill: From Promise to Pragmatism
por: Huffman, Mark D.
Publicado: (2015)

Polypill revisited – Unity in diversity
por: Dan, Gheorghe-Andrei, et al.
Publicado: (2020)

The polypill in the primary prevention of cardiovascular disease: cost-effectiveness in the Dutch population
por: van Gils, Paul F, et al.
Publicado: (2011)

Process evaluation of the impact and acceptability of a polypill for prevention of cardiovascular disease
por: Wood, Frances, et al.
Publicado: (2015)

Practical Decision Algorithms for the Use of the Cardiovascular Polypill in Secondary Prevention in Europe
por: Grigorian-Shamagian, Lilian, et al.
Publicado: (2021)

Adoption and scale-up of the cardiovascular Polypill: a realist institutional analysis
por: Abimbola, Seye, et al.
Publicado: (2022)

The Benefits of Polypill: Adherence and Chronotherapy [Response to Letter]
por: Lopez-Jaramillo, Patricio, et al.
Publicado: (2023)

Polypills for Primary Prevention of Cardiovascular Disease: A Systematic Review and Meta-Analysis
por: Kandil, Omneya A., et al.
Publicado: (2022)

Rationale and design of the Kanyini guidelines adherence with the polypill (Kanyini-GAP) study: a randomised controlled trial of a polypill-based strategy amongst Indigenous and non Indigenous people at high cardiovascular risk
por: Liu, Hueiming, et al.
Publicado: (2010)

Benefits of the Polypill on Medication Adherence in the Primary and Secondary Prevention of Cardiovascular Disease: A Systematic Review
por: Lopez-Lopez, Jose P, et al.
Publicado: (2023)

Withdrawal of cerivastatin from the world market
por: Furberg, Curt D, et al.
Publicado: (2001)

The Effectiveness of Polypill for the Prevention of Cardiovascular Disease: A Meta-Analysis of Randomized Controlled Trials
por: Virk, Ghazala S, et al.
Publicado: (2023)

Polypill for Population-Level Primary Cardiovascular Prevention in Underserved Populations—A Social Epidemiology Counterargument
por: Cainzos-Achirica, Miguel, et al.
Publicado: (2020)

Polypill for atherosclerotic cardiovascular disease prevention in Haiti: Eligibility estimates in a low-income country
por: Yan, Lily D., et al.
Publicado: (2022)

The CNIC-polypill improves atherogenic dyslipidemia markers in patients at high risk or with cardiovascular disease: Results from a real-world setting in Mexico
por: Gómez-Álvarez, Enrique, et al.
Publicado: (2020)

Cardiovascular Risk Assessment and Management in Developing Countries
por: Mendis, Shanthi
Publicado: (2005)

„Polypill“ in der kardiovaskulären Prävention – erfolgreich durch Vereinfachung?: Neue Studienergebnisse zum Nutzen der Polypill-Strategie in der Primär- und Sekundärprävention
por: Despang, Patrick, et al.
Publicado: (2023)

Current Controlled Trials in Cardiovascular Medicine: a new journal for a new age (http://cvm.controlled-trials.com)
por: Furberg , Curt, et al.
Publicado: (2000)

Randomized Polypill Crossover Trial in People Aged 50 and Over
por: Wald, David S., et al.
Publicado: (2012)

The Efficacy and Tolerability of ‘Polypills’: Meta-Analysis of Randomised Controlled Trials
por: Elley, C Raina, et al.
Publicado: (2012)

Randomized, multicenter, parallel, open, phase 4 study to compare the efficacy and safety of rosuvastatin/amlodipine polypill versus atorvastatin/amlodipine polypill in hypertension patient with dyslipidemia
por: Jung, Hae Won, et al.
Publicado: (2023)

Would primary healthcare professionals prescribe a polypill to manage cardiovascular risk? A qualitative interview study
por: Virdee, Satnam K, et al.
Publicado: (2013)

Polypill Brings Benefits to Patients with Cardiovascular Disease, Both Improving Medication Adherence and Demonstrating the Concept of Chronotherapy [Letter]
por: Zhu, Ling-Ling, et al.
Publicado: (2023)

Effect of the Polypill on Adherence and Prevention of Cardiovascular Diseases in Patients With or at High Risk of Cardiovascular Diseases: A Meta-Analysis of Randomized Controlled Trials
por: Memon, Rahat A, et al.
Publicado: (2023)

Prevention of Hypertensive Disorders of Pregnancy: a Novel Application of the Polypill Concept
por: Browne, J. L., et al.
Publicado: (2016)

Cost–benefit analysis of the polypill in the primary prevention of myocardial infarction and stroke
por: Wald, Nicholas J., et al.
Publicado: (2016)

Polypill eligibility and equivalent intake in a Swiss population-based study
por: Castioni, Julien, et al.
Publicado: (2021)

Cardiovascular disease research output in WHO priority areas between 2002 and 2011
por: Myers, Laura, et al.
Publicado: (2014)

An International Randomised Placebo-Controlled Trial of a Four-Component Combination Pill (“Polypill”) in People with Raised Cardiovascular Risk
Publicado: (2011)

Economic Burden Associated with the Treatment with a Cardiovascular Polypill in Secondary Prevention in Spain: Cost-Effectiveness Results of the NEPTUNO Study
por: Cordero, Alberto, et al.
Publicado: (2023)

The cardiovascular polypill as baseline treatment improves lipid profile and blood pressure regardless of body mass index in patients with cardiovascular disease. The Bacus study
por: Chávez Fernández, José Alejandro, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_4qluu25a5uup3r26fh4jatt038